Quemliclustat
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Quemliclustat
- Molecular weight
- 580.83
- Structure (SMILES)
- C[C@H](Nc1cc(Cl)nc2c1cnn2[C@@H]1O[C@H](COP(=O)(O)CP(=O)(O)O)[C@@H](O)[C@H]1O)c1ccccc1F
- ab 680
- AB-680
- ab680
- Ab680
- AB680
- compound 55
- COMPOUND 55
- quemliclustat
- Quemliclustat
- QUEMLICLUSTAT
- quemliclustat [INN]
- QUEMLICLUSTAT [USAN]
- Quemliclustat [WHO-DD]
- quemliclustat inn
- quemliclustat usan
- quemliclustat who dd
- CAS registry numbers
- 2105904-82-1
- ChEMBL ID
- CHEMBL4471306
- InChIKey
- MFYLCAMJNGIULC-KCVUFLITSA-N
- PubChem compound IDs
- 130205852
- FDA ingredient codes (UNII)
- J6K8WSV73A
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- quemliclustat
- Type
- Synthetic organic
- Drug name stem
- -stat
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Ecto-5'-Nucleotidase
- Gene symbol
- NT5E
- Protein identifier
- P21589
- Median affinity
- 11.3
- Affinity units
- pKi
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Cholangiocarcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005221
- Subject identifier
- D018281
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000359
- Subject identifier
- D010190
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Carcinoma, Pancreatic Ductal
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005184
- Subject identifier
- D021441
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005233
- Subject identifier
- D002289
- Condition identifier
- EFO_0000196
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0003860
- Highest recorded phase
- 1
- Condition identifier
- EFO_1000359
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0003060
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005028
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005036
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006047
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0009831
- Highest recorded phase
- 1
- NCT04104672
- NCT04381832
- NCT05329766
- NCT05676931
- NCT05688215
- NCT06048484
- NCT05915442
- NCT06048133
- Hydrogen bond acceptors
- 10
- Hydrogen bond donors
- 6
- Polar surface area
- 196.49
- Calculated partition coefficient (ALogP)
- 2.35
- Calculated partition coefficient (XLogP)
- -0.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 9
- Heavy atoms
- 37
- Molecular formula
- C20H24ClFN4O9P2
- Monoisotopic mass
- 580.0691082
- Natural product
- No
- Recorded assays
- 80
- Active assays
- 18
Active assay types
- Confirmatory
- Immune Checkpoint Inhibitors
Related records
Trials (14)
- A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
- A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
- A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers
- A Study to Investigate the Safety of AB680 in Healthy Volunteers
- Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
- Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
- An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
- Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
- Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
- Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)
- Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
- Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Study With Various Immunotherapy Treatments in Participants With Lung Cancer
- Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
In development for (9)
- Cancer Phase 2
- Cholangiocarcinoma Phase 2
- Malignant pancreatic neoplasm Phase 1
- Metastatic prostate carcinoma Phase 2
- Neoplasm Phase 2
- Non-small cell lung carcinoma Phase 2
- Pancreatic ductal adenocarcinoma Phase 2
- Pancreatic neoplasm Phase 1
- Prostate adenocarcinoma Phase 2